



## Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

November 14, 2019

DUBLIN, Nov. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at three upcoming investor conferences.

- Jefferies 2019 London Healthcare Conference in London, UK on Thursday, November 21, 2019 at 10:40 a.m. GMT / 5:40 a.m. EST. Daniel Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update.
- Piper Jaffray 31<sup>st</sup> Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2019 at 8:00 a.m. EST / 1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
- Evercore ISI 2<sup>nd</sup> Annual HealthCONx Conference in Boston, MA on Wednesday, December 4, 2019 at 8:00 a.m. EST / 1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.

A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com). Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of each webcast will be available for at least one week following each presentation on the Investors section of the company's website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

### **About Jazz Pharmaceuticals**

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines. Jazz Pharmaceuticals markets Sunosi® (solriamfetol), Xyrem® (sodium oxybate) oral solution, Defitelio® (defibrotide sodium), Erwinaze® (asparaginase *Erwinia chrysanthemi*) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Defitelio® (defibrotide), Erwinase® and Vyxeos® liposomal 44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S. For country-specific product information, please visit [www.jazzpharmaceuticals.com/medicines](http://www.jazzpharmaceuticals.com/medicines). For more information, please visit [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com) and follow us on Twitter at [@JazzPharma](https://twitter.com/JazzPharma).

### **Jazz Pharmaceuticals Contacts:**

#### **Investors:**

Kathee Littrell  
Vice President, Investor Relations  
Ireland, +353 1 634 7887  
U.S., +1 650 496 2717

#### **Media:**

Jacqueline Kirby  
Vice President, Corporate Affairs & Government Relations  
Ireland, +353 1 697 2141  
U.S., +1 215 867 4910



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-300958741.html>

SOURCE Jazz Pharmaceuticals plc